Relief All Round as FDA Clears NeoTract’s UroLift® Prostate Implant

NeoTract, Inc., has received De Novo approval from the U.S. FDA to market the novel UroLift® System, the first permanent implant to relieve low or blocked urine flow in men age 50 and older with Benign Prostatic Hyperplasia, also known as enlarged prostate.

NeoTract, Inc. Receives U.S. FDA De Novo Approval for the UroLift® Prostate Implant (via PR Newswire)

Breakthrough Technology Approved for Treatment of BPH Delivers Durable and Effective Symptom Relief while Preserving Sexual Function PLEASANTON, Calif., Sept. 16, 2013 /PRNewswire/ — NeoTract, Inc., today announced that it received De Novo approval…

published: September 19, 2013 in: Approval/Clearance, Urology

Most read

Latest

^